The Anaphylaxis Campaign and Allergy UK are facing a deluge of desperate enquiries in response to the government’s promotion of the importance and urgency of the booster vaccination. Previous information has led people living with allergies to believe that the preferred Pfizer booster will put them at risk of anaphylaxis.
The two charities, as well as the British Society for Allergy & Clinical Immunology (BSACI), are now calling for urgent action to share latest Green Book vaccination guidance. This should reassure the majority of the allergic population, who largely received AstraZeneca for first and second doses, that they can safely receive the Pfizer vaccination as a booster.
Initial concerns for people with allergies were alleviated three weeks after being raised, when guidance by the MHRA was reversed. Two healthcare workers had been reported to have suffered anaphylactic reactions to their Pfizer vaccines in the first week of the COVID-19 vaccine roll-out in December 2020. But, on investigation, there was no scientific basis for concern for the large majority of individuals with food, venom (bees and wasps) or known medicine allergies, even if they had experienced anaphylaxis before.
Unfortunately, the message that Pfizer was not suitable for people with allergies, and in particular for people with any history of anaphylaxis, spread far and wide. It has proved extremely difficult to correct this message. When the Oxford AstraZeneca vaccine was authorised, people with any allergy whatsoever were frequently told that AstraZeneca was more suitable and safer for them. So they received their two doses of that vaccine instead. This was despite the guidance by that time being very clear that there was NO REASON for them to fear the Pfizer vaccine.
People are still being turned away from vaccination centres because they report a history of anaphylaxis to food, venom, or to an identified medicine. It seems that they are often wrongly informed they need AstraZeneca as a booster, which has been noted as being less effective against COVID-19 than the Pfizer booster. The AstraZeneca vaccine is also difficult to arrange as a booster and is not usually offered in booster clinics. As a result, the charities report that patients often end up running round in circles between their GP and 119 operators, who frequently are unable to offer any guidance.
The ingredient in the Pfizer vaccine that originally caused concern is called polyethylene glycol (PEG for short, and also known as Macrogol). It is a common ingredient in medicines. Most allergic reactions caused by PEG have resulted from laxatives and some types of steroid injections. However, it is an extremely rare cause of anaphylactic reactions and ONLY individuals with a history of anaphylaxis immediately after taking medicines containing PEG need to seek further specialist allergy advice before vaccination.
As the vaccine roll-out has continued, studies have shown that even people known or suspected to have an allergy to PEG can be safely vaccinated with the Pfizer vaccine. There is just ONE case report in the medical literature of anaphylaxis with the Pfizer vaccine caused by PEG.
Key messages for patients
Â
Helpful Resources
Green Book Guidance
Allergy UK Resources
https://www.allergyuk.org/resources/anaphylaxis-and-severe-allergic-reaction-factsheet/
https://www.allergyuk.org/resources/anaphylaxis-the-four-as/
https://www.allergyuk.org/about-allergy/anaphylaxis/
https://www.allergyuk.org/news/covid-19-vaccinations-and-allergies-faq/
Anaphylaxis Campaign Resources
https://www.anaphylaxis.org.uk/covid-19-advice/covid-19-faqs/
Allergy to Polyethylene Glycols Factsheet
https://www.anaphylaxis.org.uk/wp-content/uploads/2021/12/Allergy-to-PEGs-V12.pdf
Anaphylaxis Factsheet
https://www.anaphylaxis.org.uk/wp-content/uploads/2019/07/Anaphylaxis-The-Facts-Feb-2019.pdf
British Society for Allergy and Clinical Immunology
Provide your email address to receive our printable guide outlining emergency symptoms and actions.
Additionally, enjoy our monthly Allergy Outlook email, delivering the latest news, updates, and resources directly to your inbox.